Baldwin, Eric T.
van Eeuwen, Trevor http://orcid.org/0000-0003-0549-1702
Hoyos, David
Zalevsky, Arthur http://orcid.org/0000-0001-6987-8119
Tchesnokov, Egor P.
Sánchez, Roberto
Miller, Bryant D. http://orcid.org/0009-0006-9145-8499
Di Stefano, Luciano H.
Ruiz, Francesc Xavier http://orcid.org/0000-0002-0457-0030
Hancock, Matthew
Işik, Esin
Mendez-Dorantes, Carlos http://orcid.org/0000-0002-8190-8568
Walpole, Thomas
Nichols, Charles
Wan, Paul
Riento, Kirsi
Halls-Kass, Rowan
Augustin, Martin
Lammens, Alfred
Jestel, Anja
Upla, Paula
Xibinaku, Kera
Congreve, Samantha http://orcid.org/0009-0001-5277-2235
Hennink, Maximiliaan http://orcid.org/0009-0000-1589-1780
Rogala, Kacper B. http://orcid.org/0000-0001-5997-7770
Schneider, Anna M.
Fairman, Jennifer E. http://orcid.org/0000-0002-2319-1773
Christensen, Shawn M.
Desrosiers, Brian
Bisacchi, Gregory S.
Saunders, Oliver L.
Hafeez, Nafeeza
Miao, Wenyan
Kapeller, Rosana
Zaller, Dennis M.
Sali, Andrej http://orcid.org/0000-0003-0435-6197
Weichenrieder, Oliver http://orcid.org/0000-0001-5818-6248
Burns, Kathleen H. http://orcid.org/0000-0003-1620-3761
Götte, Matthias http://orcid.org/0000-0001-6213-5806
Rout, Michael P. http://orcid.org/0000-0003-2010-706X
Arnold, Eddy http://orcid.org/0000-0003-2612-9622
Greenbaum, Benjamin D. http://orcid.org/0000-0001-6153-8793
Romero, Donna L. http://orcid.org/0000-0002-3009-1965
LaCava, John http://orcid.org/0000-0002-6307-7713
Taylor, Martin S. http://orcid.org/0000-0003-1560-9276
Article History
Received: 26 May 2023
Accepted: 7 December 2023
First Online: 14 December 2023
Competing interests
: M.S.T., B.D.G., M.G., K.H.B. and E.A. hold equity in and have received consulting fees from ROME Therapeutics. J.L. holds equity in ROME Therapeutics. D.H. and E.T. have received consulting fees from ROME Therapeutics. Research conducted at Proteros Biostructures and Charles River Laboratory was contracted by ROME Therapeutics. Research for this project in the Götte laboratory was sponsored by ROME Therapeutics. M.S.T. has received consulting fees from Tessera Therapeutics. K.H.B. declares relationships with Alamar Biosciences, Genscript, Oncolinea/PrimeFour Therapeutics, Scaffold Therapeutics, Tessera Therapeutics and Transposon Therapeutics.